Survivin在类风湿关节炎中的表达及意义  

Expression of survivin in rheumatoid arthritis

作　　者：陈进伟[1] 刘明[1] 毛妮[1] 曾艳[1] 

机构地区：[1]中南大学湘雅二医院风湿免疫科,长沙410011

出　　处：《中南大学学报（医学版）》2013年第2期186-190,共5页Journal of Central South University ：Medical Science

基　　金：国家自然科学基金(81172850)~~

摘　　要：目的:探讨存活素(survivin)与类风湿关节炎(RA)发生发展的关系,以及与难治性类风湿关节炎(RRA)多药耐药的相关性。方法:按照入组标准收集正常人15例、RA初诊未治组35例,治疗有效组20及难治组25例。采用免疫细胞化学法检测外周血淋巴细胞上survivin的表达。结果:外周血淋巴细胞中survivin阳性表达率RA初诊未治组明显升高,与正常对照组相比差异有统计学意义(χ2=29.59,P<0.01);RA治疗有效组稍有升高,与正常对照组相比差异无统计学意义(χ2=1.591,P>0.05);RA难治组明显升高,与正常对照组(χ2=26.53,P<0.01)和RA治疗有效组(χ2=24.35,P<0.01)相比差异均有统计学意义,与初诊未治组比差异无统计学意义(χ2=0.014,P>0.05)。结论:Survivin可能参与了类风湿关节炎的发病过程,可能参与难治性RA多药耐药,是难治性RA多药耐药形成机制之一。To detect the correlation between survivin and rheumatoid arthritis （RA） to determine the possible mechanism of RA and multidrug resistance in refractory rheumatoid arthritis （RRA）. Methods： We collected 15 normal controls, 35 early untreated RA patients, 20 effectively treated RA patients and 25 RRA patients according to selection standard. The expression of survivin in the peripheral blood lymphocytes was detected by immunocytochemical method.Results： There was significant difference in the survivin expression in the peripheral blood lymphocytes between the early untreated and normal control group （χ2=29.59, P〈0.01）. The survivin expression in the peripheral blood lymphocytes of effectively treated RA group slightly elevated, but had no significant difference with the normal control group （χ2=1.591, P〉0.05）. The survivin expression in the peripheral blood lymphocytes of the RRA group was significantly stronger than in the effectively treated RA group （χ2=24.35, P〈0.01）, and normal control group （χ2=26.53, P〈0.01）, with no significant difference compared with early untreated group （χ2=0.014,P〉0.05）. Conclusion： Survivin has an influential role in the occurrence and development of rheumatism arthritis. Survivin might be involved in refractory multidrug resistance of RA and be one of the multidrug resistance mechanism of RRA.

关 键 词：类风湿关节炎 多药耐药 存活素 

分 类 号：R593.22[医药卫生—内科学]